Abstract: The present disclosure relates to methods of reducing the number of abnormal PBMC cells in a leukemia patient. The methods may include administering an effective amount of a drug, which may not be indicated for leukemia, or an antibody-drug conjugate. The antibody-drug conjugate includes an antibody selected from the group consisting of an anti-?2-adrenoreceptor antibody, an anti-? adrenoceptor antibody, an anti-trace amine-associated receptor 1 antibody, an anti-dopamine receptor antibody, and an anti-serotonin receptor antibody; a drug selected from the group consisting of isoproterenol, methyldopa, olanzapine, and a derivative thereof; and a linker that conjugates the antibody and the drug.
Type:
Grant
Filed:
April 13, 2017
Date of Patent:
May 5, 2020
Assignees:
National Guard Health Affairs, King Saud bin Abdulaziz University for Health Services, King Abdullah International Medical Research Center
Inventors:
Mohamed Boudjelal, Atef Nehdi, Ahmed Sulaiman Alaskar, Imadul Islam, Hajar Mohammed Alzahrani
Abstract: The present invention relates to a device configured with an analyte sensor to measure analytes through an existing peritoneal dialysis catheter and to a method for using the device and to a method for changing of a dialysis protocol in a patient undergoing peritoneal dialysis using the device.
Type:
Grant
Filed:
March 10, 2017
Date of Patent:
November 26, 2019
Assignees:
National Guard Health Affairs, King Saud bin Abdulaziz University for Health Services, King Abdullah International Medical Research Center
Inventors:
Mahfooz Alam Farooqui, Ghassan Al Ghamdi